Evidence map›Paper›PMID 40735046›Full record

ArticleFrontiers in oncology2025

Enhanced response to dabrafenib plus trametinib in a patient with

Ettore D'Argento, Antonio Vitale, Jacopo Russo, Angelo Minucci, Alessandra Cancellieri, Alessio Stefani, Federico Monaca, Guido Horn, Denis Occhipinti, Paola Troisi and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ettore D'ArgentoComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Antonio VitaleComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Jacopo RussoComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Angelo MinucciDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Alessandra CancellieriPathology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Alessio StefaniComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Federico MonacaComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Guido HornComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Denis OcchipintiComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Paola TroisiComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Alessandro ScalaComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Sara PolidoriComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Francesco D'ArgentoUOC Radiologia e Neuroradiologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Mariantonietta Di SalvatoreComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.
Emilio BriaFaculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Giampaolo TortoraComprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico, Universitario Agostino Gemelli IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Literature evidence reports that Case description: An 85-year-old patient was diagnosed with NSCLC with the presence of MSS, Conclusions: Our clinical case represents the first report of marked efficacy of the dabrafenib-trametinib combination reported in an 85-year-old patient diagnosed with NSCLC with the presence of MSS,

Indexed as

BRAF V600Ecase reportdabrafenibnon-small-cell lung cancerRNF4trametinib

Identifiers

PMID40735046
PMCPMC12303935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.